More on ACTU
Data
Upcoming Events
News
|
|||||
|---|---|---|---|---|---|
| Prev. Close | $1.54 |
|
|||
| Open | $1.50 | ||||
| 52 Wk High | $6.07 | ||||
| 52 Wk Low | $3.89 | ||||
| Day High | $1.55 | ||||
| Day Low | $1.45 | ||||
| P/E | 9.67 | ||||
| EPS | $0.15 | ||||
| Volume | 31,075 | ||||
- H.C. Wainwright Reiterates Buy Rating on Actuate Therapeutics (ACTU)
- Form 4 ACTUATE THERAPEUTICS, For: Aug 14 Filed by: SCHMITT DANIEL M
- Form 10-Q ACTUATE THERAPEUTICS, For: Jun 30
- Rodman & Renshaw Starts Actuate Therapeutics (ACTU) at Buy
- Form 8-K ACTUATE THERAPEUTICS, For: Jul 15
- H.C. Wainwright Reiterates Buy Rating on Actuate Therapeutics (ACTU)
- Actuate's elraglusib selected for BEACON2 pediatric neuroblastoma trial
- Actuate Therapeutics’ Elraglusib Selected for Evaluation in BEACON2 Trial for High-Risk Pediatric Neuroblastoma
- Actuate presents ASCO data showing survival gains for pancreatic cancer drug
- Actuate Therapeutics Announces ASCO Poster Presentations Demonstrating Compelling Clinical and Biomarker Data for Elraglusib in First-Line Metastatic Pancreatic Cancer
Entities mentioned with ACTU
- FDA | View Related Stories »
- Mark Zuckerberg | View Related Stories »
- ARK | View Related Stories »
- Maynard Um | View Related Stories »
- S1 | View Related Stories »
- Roth Capital | View Related Stories »
- IPO | View Related Stories »
- Trading Radar | View Related Stories »
- Show More...
